Clinical trials: Transplant Recipient (Kidney)
IgA Nephropathy, Kidney Transplant Recipients
MYTP01 for Immune-Mediated Diseases
The goal of this study is to evaluate whether MYTP01, a traditional Chinese herbal formula developed by clinical experts with the assistance of artificial intelligence (AI), is effective and safe as an additional treatment for…
- Conditions
- IgA Nephropathy, Kidney Transplant Recipients, Lupus Nephritis, Primary Membranous Nephropathy
- Trial name
- NCT07901764
- Testing
- MYTP01
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Zhejiang Provincial People's Hospital
Highly Sensitized Prospective Kidney Transplant Recipients
Daratumumab and Belatacept for Desensitization
Some kidney transplant candidates have a very low chance of getting a kidney transplant because their immune systems are "highly sensitized" to most kidney donors.
- Trial name
- ATTAIN (NCT04827979)
- Testing
- daratumumab, belatacept, Bone marrow aspiration
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Infection, Bloodstream Infection
Prediction and Prevention of Bloodstream Infections After Kidney Transplantation
Kidney transplant recipients take medicines that suppress the immune system to prevent rejection of the transplanted kidney. As a result, they have a high risk of infections, especially urinary tract infections (UTIs).
- Conditions
- Kidney Transplant Infection, Bloodstream Infection, Kidney Transplant, Kidney Transplant Recipients
- Trial name
- PREDICT (NCT07407673)
- Testing
- Pivmecillinam
- Where
- 3 sites in Denmark
- Volunteers
- 180 people
- Sponsor
- Susanne Dam Nielsen, MD, DMSc
Kidney Transplant Recipient, Kidney Transplant; Complications
Vascular Complications After Kidney Transplantation
To determine the incidence of arterial inflow problems and venous outflow problems as causes of impaired renal function and/or treatment-resistant hypertension after kidney transplantation, when all kidney-transplant recipients…
- Conditions
- Kidney Transplant Recipient, Kidney Transplant; Complications, Transplant Renal Artery Stenosis, Renovascular Disease
- Trial name
- DAN-PTRAIII (NCT07531966)
- Testing
- Catheter-based angiography, Measurement of translesional pressure gradients, Intravascular ultrasound (IVUS)
- Where
- 3 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- University of Aarhus
Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC)
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
This is a phase II, multicenter, open label, single arm, non-randomized trial using Simon's optimal two-stage design to evaluate the efficacy of cemiplimab in kidney transplant recipients with advanced cutaneous squamous cell…
- Conditions
- Kidney Transplant Recipient, Cutaneous Squamous Cell Carcinoma (CSCC), Advanced Cutaneous Squamous Cell Carcinoma, Kidney Transplant
- Trial name
- CONTRAC-2 (NCT07715734)
- Testing
- Cemiplimab, Prednisone, Sirolimus
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Washington University School of Medicine
Kidney Failure, Transplant Recipient (Kidney)
Tolerance Through Mixed Chimerism (Sip-Tego)
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft.
- Conditions
- Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion
- Trial name
- NCT06972069
- Testing
- Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart)
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Tatsuo Kawai, MD, PhD
Kidney Transplant, Transplant Recipients
AI-Assisted vs Usual Follow-up in Kidney Transplantation
The goal of this clinical trial is to learn whether kidney transplant follow-up visits run by a health professional using an artificial intelligence (AI) computer helper are as good as usual follow-up visits with a doctor.
- Trial name
- FOLLOW-KTx (NCT07842289)
- Testing
- AI-Assisted Follow-up Consultation, Usual Physician-Led Follow-up Consultation
- Where
- Brazil
- Volunteers
- 140 people
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Kidney Transplant, Kidney Transplant Recipient
Rituximab in Renal Allograft Recipients Who Develop Early De Novo Anti-HLA Alloantibodies
The purpose of this study is to determine whether treatment with rituximab (anti-CD20, Rituxan®, MabThera®) in individuals who develop new anti-HLA antibodies after renal (kidney) transplant will promote longer-term survival of…
- Conditions
- Kidney Transplant, Kidney Transplant Recipient, Graft Function/Survival, de Novo HLA Antibodies Development
- Trial name
- NCT00307125
- Testing
- Rituximab plus immunosuppression
- Where
- 17 sites in United States
- Volunteers
- 757 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant Recipients
Immune Monitoring and CNI Withdrawal in Low Risk Recipients of Kidney Transplantation
The study will compare how well transplanted kidneys work and the response of people's immune systems as tacrolimus, a calcineurin inhibitor (CNI), is withdrawn.
- Trial name
- NCT01517984
- Testing
- Tacrolimus (CNI) Withdrawal, Standard Immunosuppressive Therapy
- Where
- 11 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kidney Transplant, Adult Living Donor Kidney Transplant Recipients
Treg Therapy in Subclinical Inflammation in Kidney Transplantation
The purpose of this study is: To see if polyTregs can reduce inflammation in a transplanted kidney. To find out what effects, good or bad, polyTregs will have in the kidney recipient.
- Conditions
- Kidney Transplant, Adult Living Donor Kidney Transplant Recipients, Renal Transplant, Living Kidney Donor
- Trial name
- TASK (NCT02711826)
- Testing
- Polyclonal Regulatory T Cells, Everolimus, Tacrolimus
- Where
- 6 sites in United States
- Volunteers
- 32 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Living-Donor Kidney Transplant, Kidney Transplant Recipients
Treg Modulation With CD28 and IL-6 Receptor Antagonists
The purpose of this study is to evaluate the safety of using lulizumab pegol with tocilizumab, belatacept, and everolimus in kidney transplant recipients.
- Trial name
- NCT04066114
- Testing
- lulizumab pegol, antithymocyte globulin (rabbit), methylprednisolone
- Where
- 7 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Renal Transplant Recipient
Abatacept Conversion in Kidney Transplantation
This is a single center, randomized, controlled phase 2b, conversion trial. This protocol has been developed to answer the question: Can patients be safely converted from monthly belatacept IV infusions to abatacept subcutaneous…
- Trial name
- NCT04955366
- Testing
- Belatacept, Abatacept
- Where
- United States
- Volunteers
- 87 people
- Sponsor
- Emory University
Kidney Transplant Recipient
Semaglutide for the Prevention Of Post-Transplant Diabetes Mellitus
The study aims to determine the short-term efficacy, mechanisms and safety of 24 weeks of semaglutide therapy in 37 KTR at risk of post-transplant diabetes mellitus (PTDM).
- Trial name
- SPOT-DM (NCT06913023)
- Testing
- Semaglutide 0.25 mg, Semaglutide 0.5 mg, Semaglutide 1.0 mg
- Where
- 2 sites in Canada
- Volunteers
- 37 people
- Sponsor
- University Health Network, Toronto
Transplant Recipient (Kidney)
Immune Monitoring-Guided Individualized Tacrolimus Therapy in Renal Transplant Recipients: An Observational Study and PK/PD Modeling
This study aims to resolve the clinical limitation that therapeutic drug monitoring (TDM) alone cannot accurately reflect the net immune status after kidney transplantation.
- Trial name
- NCT07815938
- Testing
- No interventional treatment, only observational data collection without clinical drug adjustment
- Volunteers
- 50 people
- Sponsor
- Zhongnan Hospital
Kidney Transplant Recipient
Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients
Most kidney transplant recipients take a combination of anti-rejection medicines for the rest of their life. One of these is called mycophenolate mofetil (MMF), also known by the brand name CellCept.
- Trial name
- OPTIMA-KT (NCT07806136)
- Testing
- Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm)
- Volunteers
- 20 people
- Sponsor
- Virginia Commonwealth University
Chronic Kidney Disease, Autoimmune Diseases
Capillary Sampling in Clinical Populations Undergoing Monitoring
Many people with long-term health conditions require regular blood tests to monitor their disease or medications. These blood tests are usually performed by taking blood from a vein during a hospital or clinic appointment.
- Conditions
- Chronic Kidney Disease, Autoimmune Diseases, Solid Organ Transplant Recipients
- Trial name
- CAPSICUM (NCT07802665)
- Testing
- Blood sampling with capillary sampling device(s)
- Volunteers
- 1,000 people
- Sponsor
- University of Edinburgh
Kidney Disease, Kidney Transplant
A Multicenter, Prospective Blood Collection Study in a Kidney Transplant Population
The purpose of this research is to collect blood samples and data from kidney transplant patients. The samples and data will be used for research and development of non-invasive test to detect donor-derived cell-free DNA…
- Conditions
- Kidney Disease, Kidney Transplant, Transplant Recipient, Renal Function
- Trial name
- Accept cfDNA (NCT07006831)
- Where
- 6 sites in United States
- Volunteers
- 400 people
- Sponsor
- Devyser Inc.
Sepsis and Septic Shock, Acute Respiratory Failure
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Kidney transplantation is the treatment of choice for end-stage chronic kidney disease. Kidney transplantation is at the first rank of solid organ transplantation in France, with 3,376 grafts performed in 2022.
- Conditions
- Sepsis and Septic Shock, Acute Respiratory Failure, Kidney Transplant Recipients, Immunosuppressive Agents
- Trial name
- REDIS (NCT06881927)
- Testing
- Hydrocortisone Hemisuccinate: 200 mg per day., reduction of the level of immunosuppression
- Where
- France
- Volunteers
- 212 people
- Sponsor
- University Hospital, Strasbourg, France
Kidney Transplant Recipients
Immunological Follow-up After SARS CoV2 Vaccination in Kidney Transplant Recipients
The investigators goal is to assess the vaccine response of kidney transplant patients following vaccination against SARS-CoV-2.
- Trial name
- COVATRHUS (NCT04757883)
- Testing
- Study of the synthesis of antibodies directed against SARS
- Where
- France
- Volunteers
- 37 people
- Sponsor
- University Hospital, Strasbourg, France
Transplant Recipient (Kidney)
Study on Precision Dosing Strategies of Anti-infective Agents in the Very Early Stage of Kidney Transplantation
This study addresses the clinical problem that reliance on serum creatinine, eGFR or empirical dosing fails to accurately adjust anti-infective doses given rapid renal function shifts within the very early 0-5 days post kidney…
- Trial name
- NCT07765615
- Volunteers
- 40 people
- Sponsor
- Zhongnan Hospital